Welcome to
Breckenridge Pharmaceutical, Inc.

 

Breckenridge Pharmaceutical, Inc. is a Towa Company. 

 TOWA PHARMACEUTICAL CO.,LTD.

We are an own label distributor that performs pharmaceutical marketing, sales and distribution in the U.S.  The company was founded in 1983 and markets a broad range of generic prescription products in several therapeutic categories and dosage forms, including tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches, and injectable products.

The Breckenridge label is recognized nationwide by wholesalers, distributors, chains, managed care accounts, and retail pharmacies.

Breckenridge, headquartered in Berlin, Connecticut, markets products under more than 40 Abbreviated New Drug Applications (ANDAs) approved by the Food and Drug Administration (FDA).                                    

 

 

Latest News

Towa completes acquisition of Esteve's Generic Division

Jan 31,2020

Berlin, CT January 31, 2020 – Breckenridge Pharmaceutical, Inc. announced today that Towa Pharmaceutical Co., Ltd. has completed its acquisition of Esteve’s generics division, including Breckenridge.

 

Towa Pharmaceutical, based in Osaka, Japan, has been dedicated to the research and development, production, and marketing of generic drugs since 1951. With a team of more than 3,100 employees, its annual sales were 105,104 million yen for the year ended March 31, 2019. Towa’s shares are listed on the Tokyo Stock Exchange (TSE).

 

Read More >>

Rivastigmine Transdermal System Approval

Dec 02,2019

Breckenridge Announces Final Approval of its ANDA for Rivastigmine Transdermal System (generic for Exelon® Patch)

 

Berlin, CT November 27, 2019– Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths (generic for Exelon® Patch by Novartis).  Breckenridge’s Rivastigmine Transdermal System was developed in collaboration with Welding GMBH & Co. KG and SK Chemicals Co., Ltd.  Exelon® Patch and its therapeutic equivalents generated annual sales of $161 million during the twelve months ending September 30, 2019, according to industry sales data. Breckenridge plans to launch the product immediately.

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories, and dosage forms; including:   tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches and injectable products The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide.

www.bpirx.com.

Read More >>

Final Approval of ANDA for Erlotinib Hydrochloride Tablets

Nov 12,2019

Berlin, CT  November 12, 2019– Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for an Abbreviated New Drug Application for Erlotinib Hydrochloride Tablets, generic for Tarceva®.  The Abbreviated New Drug Application is held by Natco Pharma Limited and the product was developed in collaboration with MEDIKL Ltd.  The product will be manufactured and supplied by Natco to Breckenridge for Breckenridge’s marketing, sale and distribution.  Breckenridge’s Erlotinib Hyrdochloride Tablets will be manufactured in EQ 25mg base, EQ 100mg base and EQ 150mg base strengths. Breckenridge plans to launch the product immediately.

 

Tarceva® and its therapeutic equivalents generated annual sales of approximately $145 million during the year ended September 30, 2019, according to industry sales data.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms, including:tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.

www.bpirx.com

 

About Natco:

Natco Pharma Limited is global generic pharmaceutical research, development manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe including the United States. Natco specializes in the development and manufacturing of oncology and other specialty pharmaceuticals.

 

About Medikl:

MEDIKL is a privately held pharmaceutical company founded in 2009. MEDIKL is committed to the development of a premium range of generic pharmaceutical products in a variety of dosage forms, including:tablets, capsules, liquids and injectable products.

 

 

Tarceva®  is a registered trademark of Genentech USA, Inc.

 

Read More >>

Product Search

All brand names are registered trademarks of their respective owner(s).